Dr. Craig Walker and Terry Roberts discuss a new class of injectable cholesterol-lowering drugs called PCSK9 inhibitors. These medications provide an additional option for lowering LDL ("bad") cholesterol beyond statin therapy alone.

Dr. Walker explains how PCSK9 normally works to block the recycling of LDL receptors in the liver, preventing further removal of LDL from the bloodstream. Two PCSK9 inhibitor drugs, Repatha and Praluent, use monoclonal antibodies to bind to PCSK9 instead, allowing LDL receptors to function properly and clear more LDL.

Viewers will learn about the mechanism of action of PCSK9 inhibitors and how they can significantly reduce cardiovascular risk by optimizing cholesterol levels.


Key Points:

• Introduction of PCSK9 inhibitors as a new class of injectable cholesterol-lowering drugs
• Explanation of how the PCSK9 protein works to block LDL receptor recycling in the liver
• Mechanism of action of PCSK9 inhibitor monoclonal antibodies like Repatha and Praluent
• Ability of PCSK9 inhibitors to further lower LDL cholesterol beyond statin therapy alone
• Potential role in optimizing cholesterol management and reducing cardiovascular risk

For more information, visit:
Facebook Page: facebook.com/profile.php?id=61558432490919
www.cardio.com